Company profile
CYTOKINETICS INC
NASDAQ:CYTKBiotechnology: Pharmaceutical Preparations
Drug pipeline (6)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| MYQORZO | approved | — | 7 | approved |
| OMECAMTIV MECARBIL | phase3 | — | 13 | active |
| TIRASEMTIV | phase3 | — | 5 | no active trials |
| ULACAMTEN | phase2 | — | 2 | active |
| SB-743921 | phase1_2 | — | 2 | no active trials |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (41)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT01380223 | phase1 | completed | 2005-08-01 | 2006-04-01 | Cytokinetics | A Pharmacokinetic and Pharmacodynamic Study of Omecamtiv Mecarbil in Healthy Volunteers |
| NCT05442775 | phase3 | terminated | 2022-08-04 | 2023-06-07 | Cytokinetics | A Phase 3, Open-Label Extension of COURAGE-ALS (CY 5031) |
| NCT03767855 | phase1 | completed | 2018-12-04 | 2020-01-03 | Cytokinetics | A Single and Multiple Ascending Dose Study of CK-3773274 in Healthy Adult Subjects |
| NCT05662215 | phase1 | terminated | 2022-12-06 | 2023-08-08 | Cytokinetics | A Single and Multiple Ascending Dose Study of CK-3828136 in Healthy Adult Participants |
| NCT05877053 | phase1 | completed | 2023-05-09 | 2024-11-20 | Cytokinetics | A Single and Multiple Ascending Dose Study of CK-4021586 in Healthy Adult Participants |
FDA applications (1)
| Application | Approved | Type | Applicant | Products | ||||
|---|---|---|---|---|---|---|---|---|
| NDA 219083 | 2025-12-19 | NDA | CYTOKINETICS INC | |||||
Loading… | ||||||||